NEW CANAAN, CT / ACCESSWIRE / May 10, 2024 / Network-1 Technologies, Inc. (NYSE American:NTIP), a company engaged in the acquisition, development, licensing, and monetization of intellectual property ...
If there's anything I've learned from years of covering the market, it's that Wall Street loves growth stocks. Fast-growing companies tend to attract investor attention and deliver stellar returns rel...
NEW CANAAN, CT / ACCESSWIRE / March 8, 2024 / Network-1 Technologies, Inc. (NYSE American:NTIP) ("Network-1"), a company engaged in acquiring, developing, licensing, and monetizing intellectual proper...
NEW CANAAN, CT / ACCESSWIRE / March 1, 2024 / Network-1 Technologies, Inc. (NYSE American:NTIP), a company engaged in the acquisition, development, licensing, and monetization of intellectual property...
NEW CANAAN, CT / ACCESSWIRE / February 23, 2024 / Network-1 Technologies, Inc. (NYSE American:NTIP) today announced that its Board of Directors has declared a semi-annual cash dividend of $0.05 per co...
NEW CANAAN, CT / ACCESSWIRE / November 2, 2023 / Network-1 Technologies, Inc. (NYSE American:NTIP), a company specializing in the development, licensing, and monetization of its intellectual property ...
NEW CANAAN, CT / ACCESSWIRE / September 8, 2023 / Network-1 Technologies, Inc. (NYSE American:NTIP) today announced that its Board of Directors has declared a semi-annual cash dividend of $0.05 per co...
NEW CANAAN, CT / ACCESSWIRE / September 6, 2023 / Network-1 Technologies, Inc. (NYSE American:NTIP), a company engaged in the acquisition, development, licensing, and monetization of intellectual prop...
NEW CANAAN, CT / ACCESSWIRE / August 28, 2023 / Network-1 Technologies, Inc. (NYSE American:NTIP), a company engaged in the acquisition, development, licensing, and monetization of intellectual proper...
NEW CANAAN, CT / ACCESSWIRE / August 10, 2023 / Network-1 Technologies, Inc. (NYSE AMERICAN:NTIP), a company specializing in the development, licensing, and monetization of its intellectual property a...
Network-1 is selling near its cash liquidation value, refusing to discount future upside catalysts. New buyers can capture a speculative biotech investment, an interest in several patent infringement ...